Immunovant (IMVT) Equity Ratio (2018 - 2026)

Immunovant has reported Equity Ratio for 9 years, with the latest figure at 0.89 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 2.25% year-over-year to 0.89; the trailing twelve-month figure through Mar 2026 stood at 0.89 (down 2.25% YoY), and the FY2026 full-year result was 0.89, down 2.25% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.89, down from 0.94 in the prior quarter.
• The five-year high for Equity Ratio was 0.95 in Q4 2023, with the low at 0.84 in Q4 2024.
• Historically, Equity Ratio has averaged 0.9 across 5 years, with a median of 0.91 in 2022.
• Annual changes were most pronounced in 2024 — Equity Ratio retreated 12.27% — and 2025, when it advanced 11.86%.
• Immunovant's Equity Ratio stood at 0.91 in 2022, then advanced by 5.06% to 0.95 in 2023, then dropped by 12.27% to 0.84 in 2024, then gained by 11.86% to 0.94 in 2025, then dropped by 4.93% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.94 (Q4 2025), and 0.89 (Q3 2025), per Business Quant data.